Discover trends, market shifts, and competitive outlooks for the filgrastim biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Is the Current and Projected Market Size of the Filgrastim Biosimilars Market Through 2034?

The market for filgrastim biosimilars has seen robust growth in the past few years. The market value is estimated to escalate from $0.92 billion in 2024 to approximately $0.98 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 6.9%. This growth noted in the previous period is associated with the rise in emerging markets, an increase in patent expiration, government initiatives, escalated healthcare expenditure, reduced biosimilars costs, a reliable drug pipeline, and a surge in biopharmaceutical R&D spending.

The market size for filgrastim biosimilars is predicted to exhibit robust growth in the upcoming years, achieving a worth of $1.21 billion in 2029 with a compound annual growth rate (CAGR) of 5.4%. The growth during the forecast period is due to factors such as an aging population and expanded access to healthcare. Dominant trends anticipated in the forecast period involve considerable investment into Research & Development for generating innovative and effective biosimilars, the manufacture of biosimilars for neutropenia treatment to boost revenues, and enhanced focus on mergers and acquisitions as growth strategies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4016&type=smp

What Are the Major Market Drivers Behind the Rising Adoption of Filgrastim Biosimilars Market?

The uptick seen in cases of neutropenia is anticipated to push forward the expansion of the filgrastim biosimilar market. Neutropenia is an ailment characterized by low levels of neutrophils, a crucial type of white blood cell that combats infections. Filgrastim biosimilars enhance the production of neutrophils in our bone marrow, increasing the neutrophil count and helping to combat infections. For example, data from the National Center for Biotechnology Information, a US biomedical literature database, showed that in August 2022, the frequency of neutropenia was 0.38% in Mexican-Americans, 0.79% in whites, and 4.5% in black participants. Consequently, the rising occurrence of neutropenia is fuelling the progression of the filgrastim biosimilar market.

Which Key Market Segments Comprise the Filgrastim Biosimilars Market and Drive Its Revenue Growth?

The filgrastim biosimilars market covered in this report is segmented –

1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization

2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities, Company-Owned Production Plants, Vertically Integrated Manufacturing

2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing, Fill and Finish Services, API (Active Pharmaceutical Ingredient) Manufacturing, Specialized Biosimilar Manufacturing Services

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=4016&type=smp

Which Areas Are Leading Regions in the Filgrastim Biosimilars Market Expansion Across the Globe?

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Strategic Trends Steering theFilgrastim Biosimilars Market Direction?

Major firms in the filgrastim biosimilar market are focusing on the creation of innovative products that incorporate advanced technologies, such as recombinant DNA technology, into their biosimilars production. This technique involves the generation of hybrid or chimeric DNA by integrating a foreign sequence into an organism’s DNA. To illustrate, in May 2023, Amneal Pharmaceuticals, located in the US, introduced FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen’s NEULASTA. The product was launched in the US with an indication for the treatment and prevention of febrile neutropenia. It enhances the expansion and specialization of precursor cells-derived neutrophils, induces their maturation, and increases the survival and efficacy of fully mature neutrophils, leading to neutrophil count increases dependent on dosage. The introduction of Fylnetra fosters the next generation of cost-effective medicines and promotes widespread accessibility for patients, healthcare providers, and payors.

View the full report here:

https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

How Is the Filgrastim Biosimilars Market Conceptually Defined?

Filgrastim biosimilars refer to a biosimilar that is intended to treat patients who suffer bone marrow damage from extremely high radiation doses in a manner similar to how it helps cancer patients by stimulating the formation of white blood cells, making patients less susceptible to infections.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=4016

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model